Antitumor effect of cotylenin A plus interferon-α:: Possible therapeutic agents against ovary carcinoma

被引:31
作者
Honma, Y
Kasukabe, T
Yamori, T
Kato, N
Sassa, T
机构
[1] Shimane Univ, Fac Med, Dept Life Sci, Izumo, Shimane 6938501, Japan
[2] Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Tokyo 170, Japan
[3] Osaka Univ, Inst Sci & Ind Res, Osaka, Japan
[4] Yamagata Univ, Dept Bioresource Engn, Tsuruoka, Japan
关键词
interferon-alpha; TRAIL; apoptosis; ovary carcinoma; cotylenin A; combination therapy; antitumor agent;
D O I
10.1016/j.ygyno.2005.07.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Recently, we found that cotylenin A and IFN alpha synergistically inhibited growth both in vitro and in vivo, and induced apoptosis in human cancer eel Is. For the clinical application of this combined treatment, suitable cancer targets should be selected. Methods. We examined the combined effects of these compounds on various types of cancer cells by a human cancer cell line panel assay, and on cancer cells that had been freshly isolated from patients in three-dimensional cultures embedded in collagen gel. Results. In the analysis of 39 cancer cell lines, ovarian cancer cells were highly sensitive to combined treatment with cotylenin A and IFN alpha in inhibiting cell growth. This treatment was also effective toward ovarian cancer cells that were refractory to CDDP, and significantly inhibited the growth of ovarian cancer cells as xenografts without apparent adverse effects. Ovarian cancer cells from the patients were also sensitive to the combined treatment in primary cultures. Conclusion. Combined treatment with cotylenin A and IFN alpha may have therapeutic value in treating ovarian cancer. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:680 / 688
页数:9
相关论文
共 24 条
[1]   Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha 2a in pediatric patients with refractory cancer [J].
Adamson, PC ;
Reaman, G ;
Finklestein, JZ ;
Feusner, J ;
Berg, SL ;
Blaney, SM ;
OBrien, M ;
Murphy, RF ;
Balis, FM .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (11) :3330-3337
[2]   Apoptosis and interferons: Role of interferon-stimulated genes as mediators of apoptosis [J].
Chawla-Sarkar, M ;
Lindner, DJ ;
Liu, YF ;
Williams, B ;
Sen, GC ;
Silverman, RH ;
Borden, EC .
APOPTOSIS, 2003, 8 (03) :237-249
[3]   A PHASE-2 STUDY ON ESCALATING INTERFERON DOSES IN ADVANCED OVARIAN-CARCINOMA [J].
EINHORN, N ;
LING, P ;
EINHORN, S ;
STRANDER, H .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1988, 11 (01) :3-6
[4]  
FREEDMAN RS, 1983, J BIOL RESP MODIF, V2, P133
[5]  
FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
[6]   Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents [J].
Goto, I ;
YamamotoYamaguchi, Y ;
Honma, Y .
BRITISH JOURNAL OF CANCER, 1996, 74 (04) :546-554
[7]   Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study [J].
Hall, GD ;
Brown, JM ;
Coleman, RE ;
Stead, M ;
Metcalf, KS ;
Peel, KR ;
Poole, C ;
Crawford, M ;
Hancock, B ;
Selby, PJ ;
Perren, TJ .
BRITISH JOURNAL OF CANCER, 2004, 91 (04) :621-626
[8]   Treatment of human promyelocytic leukemia in the SLID mouse model with cotylenin A, an inducer of myelomonocytic differentiation of leukemia cells [J].
Honma, Y ;
Ishii, Y ;
Sassa, T ;
Asahi, K .
LEUKEMIA RESEARCH, 2003, 27 (11) :1019-1025
[9]  
Honma Y, 2003, CANCER RES, V63, P3659
[10]   Cotylenin A - A plant growth regulator as a differentiation-inducing agent against myeloid leukemia [J].
Honma, Y .
LEUKEMIA & LYMPHOMA, 2002, 43 (06) :1169-1178